These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 26291415)

  • 21. Histopathological features in leprosy, post-kala-azar dermal leishmaniasis, and cutaneous leishmaniasis.
    Singh A; Ramesh V
    Indian J Dermatol Venereol Leprol; 2013; 79(3):360-6. PubMed ID: 23619440
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Interpretation and recollection different.
    Ackerman AB
    J Cutan Pathol; 2006 Jan; 33(1):57-8; author reply 59-60. PubMed ID: 16441414
    [No Abstract]   [Full Text] [Related]  

  • 23. What to call the LEJC-BFV nevus?
    Glusac EJ
    J Cutan Pathol; 2004 Sep; 31(8):521-2. PubMed ID: 15268705
    [No Abstract]   [Full Text] [Related]  

  • 24. Diagnostic Immunohistochemistry: What Can Go Wrong and How to Prevent It.
    Gown AM
    Arch Pathol Lab Med; 2016 Sep; 140(9):893-8. PubMed ID: 27575264
    [TBL] [Abstract][Full Text] [Related]  

  • 25. War and peace in the realm of dysplastic nevi.
    Cramer SF
    J Cutan Pathol; 2005 Apr; 32(4):319-20. PubMed ID: 15769285
    [No Abstract]   [Full Text] [Related]  

  • 26. Pitfalls in diagnostic immunohistology.
    Leong AS
    Adv Anat Pathol; 2004 Mar; 11(2):86-93. PubMed ID: 15090844
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Quantitative in situ proteomics; a proposed pathway for quantification of immunohistochemistry at the light-microscopic level.
    Taylor CR
    Cell Tissue Res; 2015 Apr; 360(1):109-20. PubMed ID: 25620411
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Demonstration techniques in cellular pathology: putting things into perspective.
    Cook HC
    Med Lab Sci; 1990 Jul; 47(3):210-9. PubMed ID: 1698244
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Aptahistochemistry in diagnostic pathology: technical scrutiny and feasibility.
    Bukari BA; Citartan M; Ch'ng ES; Bilibana MP; Rozhdestvensky T; Tang TH
    Histochem Cell Biol; 2017 May; 147(5):545-553. PubMed ID: 28321500
    [TBL] [Abstract][Full Text] [Related]  

  • 30. On bossing: taking charge without the facts.
    Wassef C; Serna-Tamayo C; McDonough P; Tumer G; Lambert WC
    Skinmed; 2012; 10(6):385-6. PubMed ID: 23346667
    [No Abstract]   [Full Text] [Related]  

  • 31. Challenges and pitfalls in HNPCC screening by microsatellite analysis and immunohistochemistry.
    Müller A; Giuffre G; Edmonston TB; Mathiak M; Roggendorf B; Heinmöller E; Brodegger T; Tuccari G; Mangold E; Buettner R; Rüschoff J;
    J Mol Diagn; 2004 Nov; 6(4):308-15. PubMed ID: 15507669
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Appearances in dermatopathology: the diagnostic and the deceptive.
    Madke B; Doshi B; Khopkar U; Dongre A
    Indian J Dermatol Venereol Leprol; 2013; 79(3):338-48. PubMed ID: 23619438
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [A comparative evaluation of immunohistochemical markers for the differential diagnosis between malignant mesothelioma, non-small cell carcinoma involving the pleura, and benign reactive mesothelial cell proliferation].
    Szczepulska-Wójcik E; Langfort R; Roszkowski-Sliz K
    Pneumonol Alergol Pol; 2007; 75(1):57-69. PubMed ID: 17541913
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The use of immunohistochemistry in an oral pathology laboratory.
    Ajura AJ; Sumairi I; Lau SH
    Malays J Pathol; 2007 Dec; 29(2):101-5. PubMed ID: 19108402
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A two-phase study model for the standardization of HER2 immunohistochemical assay on invasive ductal carcinoma of the breast.
    Sampatanukul P; Chaiwun B; Wongwaisayawan S; Suwanagool P; Vinyuvat S; Karalak A; Praditphol N; Paueksakon P; Ruangvejvorachai P; Field AS; Wannakrairot P
    J Med Assoc Thai; 2005 Nov; 88(11):1680-8. PubMed ID: 16471119
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Institutional quality assurance for breast cancer HER2 immunohistochemical testing: identification of outlier results and impact of simultaneous fluorescence in situ hybridization cotesting.
    Green IF; Zynger DL
    Hum Pathol; 2015 Dec; 46(12):1842-9. PubMed ID: 26412217
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Anaplastic lymphoma kinase (ALK1) immunohistochemistry in diagnostic dermatopathology; an update.
    Papalas JA; Kulbacki E; Wang E
    Am J Dermatopathol; 2013 Jun; 35(4):403-8; quiz 409-11. PubMed ID: 23689691
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Interlaboratory trial 2000 " Immunohistochemistry" of the German Society for Pathology and the Professional Association of German Pathologists].
    Rüdiger T; Höfler H; Kreipe HH; Nizze H; Pfeifer U; Stein H; Dallenbach E; Fischer HP; Mengel M; Von Wasielewski R; Müller-Hermelink K; ;
    Pathologe; 2003 Feb; 24(1):70-8. PubMed ID: 12601481
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tissue microarrays are an effective quality assurance tool for diagnostic immunohistochemistry.
    Hsu FD; Nielsen TO; Alkushi A; Dupuis B; Huntsman D; Liu CL; van de Rijn M; Gilks CB
    Mod Pathol; 2002 Dec; 15(12):1374-80. PubMed ID: 12481020
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Utilization of a TFE3 break-apart FISH assay in a renal tumor consultation service.
    Green WM; Yonescu R; Morsberger L; Morris K; Netto GJ; Epstein JI; Illei PB; Allaf M; Ladanyi M; Griffin CA; Argani P
    Am J Surg Pathol; 2013 Aug; 37(8):1150-63. PubMed ID: 23715164
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.